IRulya Therapeutics Inc.
IRLAHealthcare|Biotechnology|US
$31.00
+1.69 (+5.77%)
Tangible Book / Share
$17.69
Cash / Share
$18.91
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05798923 LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | Pulmonary Hypertension Due to Lung Diseases and Hypoxia | P2 | Recruiting | 85 | RCT, Double-blind | Placebo, LAM-001 |
| NCT06018766 LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome. | Bronchiolitis Obliterans Syndrome, Chronic Lung Allograft Dysfunction | P2 | Recruiting | 30 | RCT, Double-blind | LAM-001, Placebo |
| NCT05163886 Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis, ALS | P2 | Completed | 15 | RCT, Double-blind | LAM-002A |
| NCT07886554 LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH) | Sarcoidosis Associated Pulmonary Hypertension | P2 | Not Yet Recruiting | 60 | RCT, Double-blind | Placebo, LAM-001, LAM-001 |
| NCT04446377 A Study of LAM-002A for the Prevention of Progression of COVID-19 | COVID-19 Disease | P2 | Completed | 142 | RCT, Double-blind | Apilimod Dimesylate Capsule |
| NCT03426605 A Study of LAM-003 in Patients With Acute Myeloid Leukemia | Oncology, Acute Myeloid Leukemia | P1 | Completed | 17 | Open-label | Open Label LAM-003 |
| NCT02594384 A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma | Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic | P1 | Completed | 62 | Open-label | LAM-002A, Rituximab, Atezolizumab |
| NCT05483322 An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD) | Frontotemporal Dementia | NO_LONGER_AVAILABLE | — | — | LAM-002A |